Treatment of Alopecia Areata with Simvastatin and Ezetimibe

This study reported that oral simvastatin/ezetimibe therapy was ineffective for treating alopecia areata, with 67% of participants experiencing no hair regrowth. Additionally, 24% of patients experienced adverse effects, including myalgia, highlighting the need to weigh potential risks against questionable benefits.

This research overview highlights that although JAK inhibitors show promise as potential treatments for alopecia areata based on recent insights into the disease mechanism, their efficacy has not yet been thoroughly evaluated in a systematic manner.

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

This article reviews the clinical presentation and histopathologic features of alopecia areata and proposes a hypothesis for its development, but it reports no new clinical results.